ACN Newswire
TOKYO and CAMBRIDGE, Mass., Oct 17, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-solubleaggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI)due to Alzheimer’s disease (AD) and mild AD dementia.Eisai will request a reconsideration of this decision under Section 60* of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia…
Read More
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in Australia
Raleigh Schroeder
15:26
TOKYO and CAMBRIDGE, Mass., Oct 17, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-solubleaggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment
